Population pharmacokinetics and exposure–response of anti‐programmed cell death protein‐1 monoclonal antibody dostarlimab in advanced solid tumours

AIM: Develop a population pharmacokinetic (PopPK) model to characterise the pharmacokinetics (PK) of anti‐programmed cell death protein‐1 (PD‐1) antibody dostarlimab, identify covariates of clinical relevance, and investigate efficacy/safety exposure–response (ER) relationships. METHODS: A PopPK mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Melhem, Murad, Hanze, Eva, Lu, Sharon, Alskär, Oskar, Visser, Sandra, Gandhi, Yash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543385/
https://www.ncbi.nlm.nih.gov/pubmed/35357027
http://dx.doi.org/10.1111/bcp.15339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543385/
https://www.ncbi.nlm.nih.gov/pubmed/35357027
http://dx.doi.org/10.1111/bcp.15339

Ejemplares similares